Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bioadaptives (BDPT) Common Equity (2019 - 2025)

Bioadaptives' Common Equity history spans 7 years, with the latest figure at -$1.5 million for Q3 2025.

  • For Q3 2025, Common Equity rose 18.84% year-over-year to -$1.5 million; the TTM value through Sep 2025 reached -$1.5 million, up 18.84%, while the annual FY2024 figure was -$1.5 million, 11.1% up from the prior year.
  • Common Equity for Q3 2025 was -$1.5 million at Bioadaptives, down from -$1.2 million in the prior quarter.
  • Across five years, Common Equity topped out at -$1.0 million in Q1 2021 and bottomed at -$1.9 million in Q2 2024.
  • The 5-year median for Common Equity is -$1.5 million (2025), against an average of -$1.5 million.
  • The largest annual shift saw Common Equity crashed 57.56% in 2024 before it soared 34.07% in 2025.
  • A 5-year view of Common Equity shows it stood at -$1.1 million in 2021, then tumbled by 32.79% to -$1.5 million in 2022, then dropped by 13.44% to -$1.6 million in 2023, then grew by 11.1% to -$1.5 million in 2024, then decreased by 0.09% to -$1.5 million in 2025.
  • Per Business Quant, the three most recent readings for BDPT's Common Equity are -$1.5 million (Q3 2025), -$1.2 million (Q2 2025), and -$1.6 million (Q1 2025).